The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1563
January 14, 2019
View Complete Issue         Table of Contents 2019 
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
January 14, 2019 (Issue: 1563)
Tildrakizumab-asmn (Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
Article code: 1563b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.